HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 03-13-2004, 02:30 PM   #1
Paul
Guest
 
Posts: n/a
Genomic Health recently announced that its breast cancer assay Oncotype DX™ is now available for clinical use in most states. Oncotype DX™ is a clinically validated assay that evaluates a tumor’s expression of 21 genes and quantifies the likelihood of a distant recurrence in women with node negative ER positive breast cancer.

Oncotype DX™ was prospectively validated by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that involved 668 women with node negative ER-positive breast cancer treated with tamoxifen. The Recurrence Score™ is calculated from the tumor’s expression of 21 genes which include those measuring proliferation HER-2 estrogen and invasion. The scale of the score is 1-100. Patients with a score of <18 have a low risk of recurrence those with a score of 18-31 have an intermediate risk and those with a score of 31 or more have a high risk of relapse.
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 01:37 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter